ERBB2 and breast cancer: Notably, HER2 mRNA levels, which are highly heterogeneous among HER2-positive BC specimens [16,19,20,21,22], were found to provide additional response information to PAM50 [17,19], and the combined assessment increased the accuracy of anti-HER2 sensitivity prediction compared to that determined with a single marker [19].